REG - Abingdon Health PLC - Admission to trading on OTCQB in the US

Abingdon HealthAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260421:nRSU1913Ba&default-theme=true

RNS Number : 1913B  Abingdon Health PLC  21 April 2026

 

Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

 

Admission to trading on OTCQB Venture Market in the US

 

York, UK and Madison, WI, USA, 21 April 2026: Abingdon Health plc (AIM: ABDX)
(OTCQB: ABDXF), a leading international developer, manufacturer and regulatory
services provider for rapid diagnostic tests and med-tech, announces that
trading in the Company's ordinary shares will begin today at 9.30am EST on the
OTCQB Venture Market ("OTCQB") in the United States, under the ticker symbol
"ABDXF".

 

The OTCQB is designed for entrepreneurial and development stage US and
international companies. Foreign Private Issuers, such as Abingdon Health,
that trade on the OTCQB are exempt under the US Exchange Act Rule 12g3-2(b)
from SEC reporting if they make whatever information is required by their home
market regulator publicly available to US investors in English. Abingdon
Health will therefore face no extra reporting obligations and incur minimal
ongoing costs as a result of the Company's Ordinary Shares being traded on the
OTCQB.

 

Abingdon Health's Ordinary Shares will continue to trade on the London Stock
Exchange's AIM Market under the symbol "ABDX".

 

Any shareholders wishing to keep up to date with Abingdon Health news, please
email abingdon@walbrookpr.com

 

Enquiries:

 

 Abingdon Health plc                           www.abingdonhealth.com/investors/ (http://www.abingdonhealth.com/investors/)
 Chris Hand, Executive Chairman                                                         Via Walbrook PR

 Tom Hayes, CFO

 Cavendish Capital Markets Limited (Sole Broker and Nominated Adviser)                    Tel: +44 (0)20 7220 0500
 Geoff Nash / Isaac Hooper / Joe Smith (Corporate Finance)

 Nigel Birks (Life Science Specialist Sales)

 Walbrook PR (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
                                               (mailto:abingdon@walbrookpr.com)
 Paul McManus / Alice Woodings                 Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About Abingdon Health

 

Abingdon Health Group is a leading med-tech contract service provider
offering its services to an international customer base.

 

The Group's CDMO
(https://www.abingdonhealth.com/services/lateral-flow-cdmo-development)
(Contract Development and Manufacturing Organisation) expertise offers lateral
flow product development
(https://www.abingdonhealth.com/services/your-complete-lateral-flow-partner/)
, regulatory strategy support, technology transfer and manufacturing services
(https://www.abingdonhealth.com/services/lateral-flow-scale-up-technical-transfer)
for customers looking to develop new assays or transfer existing
laboratory-based assays to a lateral flow format.  Abingdon Health has the
internal capabilities to take lateral flow projects, in areas such as
infectious disease and clinical testing
(https://www.abingdonhealth.com/services/your-complete-lateral-flow-partner/)
, including companion diagnostics
(https://www.abingdonhealth.com/services/companion-diagnostics-ivd-cdmo) ,
animal health and environmental testing, from initial concept through to
routine manufacturing; from idea to commercial success.

 

Abingdon's regulatory services
(https://www.abingdonhealth.com/services/regulatory-services/) companies,
Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of
regulatory services to the in vitro diagnostic and wider medical device
industry, to support customers in bringing products to market across a range
of territories including the USA, EU and the UK. Its consultancy services
range from design, implementation and maintenance of quality management
systems, preparation of technical files for regulatory approvals, part-time
and interim management support, auditing both internal and external,
management reviews and presentations, training and mentoring.  The Company's
subsidiary, Abingdon Analytical Ltd, offers analytical testing and performance
evaluation
(https://www.abingdonhealth.com/services/performance-evaluation-services/) to
generate the required technical and data for regulatory approval for lateral
flow and other in vitro diagnostic assays from its Doncaster, England
facilities.

 

Founded in 2008, Abingdon Health is headquartered in York, England with
laboratories in Doncaster, England and laboratories and commercial offices in
Madison, Wisconsin, USA.

 

Abingdon Health's brochures
(https://www.abingdonhealth.com/knowledge-centre/brochures-guides)  outlines
the comprehensive support the Group can now provide to its international
customers.  For more information visit: www.abingdonhealth.com
(http://www.abingdonhealth.com) .

 

LEI - 213800XFI4WV3FBILO20

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPUCACUPQGAU



            Copyright 2019 Regulatory News Service, all rights reserved